Every 10-Q that Fulcrum Therapeutics, Inc. (FULC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FULC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FULC filings page.
Fulcrum Therapeutics, a rare‑disease drug developer, reported continued losses while fundamentally reshaping the business. After end‑of‑phase FDA feedback raised concerns about pociredir’s benefit‑risk profile in sickle cell disease, the company discontinued the program, ceased all research and development activities, and cut its workforce by about 85% from 57 to nine employees. Management is now conducting a comprehensive review of strategic alternatives, including a merger, acquisition, asset sale or licensing transaction, with Leerink Partners advising.
For the six months ended June 30, 2026, Fulcrum recorded a net loss of $45.1 million, compared with $35.0 million a year earlier, including $5.1 million of long‑lived asset impairments and $4.3 million of restructuring charges. Cash used in operations was $34.8 million. The company ended June with $318.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $639.3 million, and believes this liquidity will fund operating and capital needs for at least 12 months while it pursues potential transactions.
Fulcrum Therapeutics reports Q1 2026 results with a net loss of $18.9 million, slightly wider than the prior-year period. Research and development expense was $14.1 million and general and administrative expense was $8.1 million as the company advances its rare-disease pipeline.
Lead candidate pociredir in sickle cell disease showed encouraging 20 mg PIONEER cohort data: mean absolute HbF rose 12.2% to 19.3%, 58% of patients reached HbF ≥20%, hemoglobin increased 1.1 g/dL, and vaso-occlusive crises fell versus expected events, with a generally well-tolerated safety profile.
Fulcrum ended the quarter with $333.3 million in cash, cash equivalents, and marketable securities and projects this will fund operations into 2029, while it narrows focus on pociredir and core benign hematology programs and exits the CAMP4 bone marrow failure collaboration.
Fulcrum Therapeutics (FULC) filed its Q3 2025 10‑Q, reporting continued operating focus on sickle cell candidate pociredir alongside tighter expenses. The quarter showed a net loss of $19.6 million on operating expenses of $21.9 million (R&D $14.3 million; G&A $7.6 million). Cash, cash equivalents, and marketable securities totaled $200.6 million as of September 30, 2025, and management states this should fund operations for at least 12 months from issuance. The accumulated deficit was $573.9 million.
Clinical update: In the 12 mg Phase 1b cohort (n=16), pociredir increased mean absolute fetal hemoglobin (HbF) by 8.6% at 12 weeks (7.6% to 16.2%); 7 of 16 exceeded 20% HbF. Hemolysis markers improved and mean hemoglobin rose by 0.9 g/dL. Safety was generally well-tolerated with no drug‑related serious adverse events or discontinuations. Enrollment in the 20 mg cohort (n=12) is complete, with data expected by the end of 2025.
There was no collaboration revenue in Q3 2025 (vs. $80.0 million in the first nine months of 2024 from a now-terminated Sanofi agreement). Shares outstanding were 54,118,438 as of October 22, 2025.